TCM
KURA icon

Triumph Capital Management’s Kura Oncology KURA Stock Holding History

Triumph Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$428 Hold
39
– – ﹤0.01% 1746
2026
Q1 		$317 Hold
39
– – ﹤0.01% 1736
2025
Q4 		$405 Buy
+39
New +$409 ﹤0.01% 1671

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Triumph Capital Management's KURA Position: Q2 2026 in Review

Triumph Capital Management held its Kura Oncology (KURA) position steady in Q2 2026 at 39 shares worth $428. The position accounts for ﹤0.01% of the portfolio, ranked #1746.

Triumph Capital Management first reported a position in KURA in Q4 2025 and has held it in 3 quarters since. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Triumph Capital Management held 39 shares of Kura Oncology worth $428 as of Q2 2026.
  • Triumph Capital Management left its Kura Oncology share count unchanged in Q2 2026.
  • Kura Oncology made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1746 holding.
  • Triumph Capital Management first reported a position in Kura Oncology in Q4 2025 and has held it in 3 quarters since.
  • 221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.